



Australian
Commission on
Safety and Quality
in Health Care

NPAAC

National Pathology
Accreditation Advisory Council

Requirements for the Development and Use of In-House In Vitro Diagnostic Medical Devices

Fifth Edition

Published by the Australian Commission on Safety and Quality in Health Care

Level 5, 255 Elizabeth Street, Sydney NSW 2000

Phone: (02) 9126 3600

Email: mail@safetyandquality.gov.au

Website: www.safetyandquality.gov.au

ISBN: 978-1-76007-339-8

© Australian Commission on Safety and Quality in Health Care 2025

All material and work produced by the Australian Commission on Safety and Quality in Health Care (the Commission) is protected by copyright. The Commission reserves the right to set out the terms and conditions for the use of such material.

As far as practicable, material for which the copyright is owned by a third party will be clearly labelled. The Commission has made all reasonable efforts to ensure that this material has been reproduced in this publication with the full consent of the copyright owners.

With the exception of any material protected by a trademark, any content provided by third parties and where otherwise noted, all material presented in this publication is licensed under a

[Creative Commons Attribution-Non-commercial-No Derivatives 4.0 International licence](https://creativecommons.org/licenses/by-nc-nd/4.0/).



If you would like to reproduce all or part of this resource, please complete our online form at safetyandquality.gov.au/permission-request.

The Commission's preference is that you attribute this publication (and any material sourced from it) using the following citation:

Australian Commission on Safety and Quality in Health Care. NPAAC Requirements for the development and use of In-house In Vitro Diagnostic Medical Devices. 5th Ed. Sydney: ACSQHC; 2025.

Disclaimer

The content of this document is published in good faith by the Commission for information purposes. The document is not intended to provide guidance on healthcare choices. You should contact your health care provider for information or advice on healthcare choices.

The Commission does not accept any legal liability for any injury, loss or damage incurred using, or reliance on, this document.

Acknowledgement

We acknowledge the Traditional Owners and Custodians of Country throughout Australia. We recognise their continuing connection to land, waters and community and acknowledge their ongoing contribution to the health system and community. We pay our respects to Elders past and present.

Updates

Requirement Edition	Year	Changes
First Edition	2004	First published.
Second Edition	2007	Introduced ISO 15189 aligned requirements.
Third Edition	2014	Reprinted and reformatted to be read in conjunction with the <i>Requirements for Medical Pathology Services</i> .
Fourth Edition	2018	Revised for alignment with the Therapeutic Goods Administration in-house IVD regulatory framework.
Fifth Edition	2025	Introduced a new companion diagnostics (CDx) framework, including CDx validation and clinical trial assay equivalence requirements (Standard 8), and updates to the new Commission template with removal of references to the <i>Requirements for Medical Pathology Services</i> .

Contents

Background	4
Introduction	6
Terminology	8
Context	11
Standards	15
1. General requirements	16
2. Design	19
3. Production and contracted services	21
4. Analytical performance	24
5. Scientific validity	28
6. Clinical performance	29
7. Clinical utility	30
8. Companion diagnostics	32
9. Multivariate index assays	34
10. Monitoring, analysis and improvement	35
11. Adverse events and recalls	37
12. Documentation	40
Appendix A: Essential Principles	44
Appendix B: Classification rules for IVDs	45
Appendix C: Procedures applying to in-house IVD medical devices	46
Appendix D: Frequently answered questions and examples for guidance	47
References	50
Bibliography	51

Background

The Australian Commission on Safety and Quality in Health Care leads and coordinates national improvements in health care safety and quality.

About the Australian Commission on Safety and Quality in Health Care

The Australian Commission on Safety and Quality in Health Care (the Commission) partners with the Australian Government, state and territory governments and the private sector to achieve a safe, high-quality, sustainable health system. It also works closely with patients, carers, clinicians, medical scientists, managers, healthcare organisations and policymakers.

Key functions of the Commission include:

- developing national safety and quality standards
- developing clinical care standards to improve the implementation of evidence-based health care
- coordinating work in specific areas to improve outcomes for patients
- providing information, publications and resources about safety and quality.

The Commission works in four priority areas:

- High-quality care in an evolving environment
- Strong, outcome-focused clinical governance
- Empowered patients, carers and communities
- An improvement driven workforce culture.

About the National Pathology Accreditation Scheme

The National Pathology Accreditation Scheme (NPAS) is an accreditation scheme that requires pathology practices to meet relevant standards for their pathology services to be eligible for Medicare benefits. The *Health Insurance (Accredited Pathology Laboratory-Approval) Principles 2017* (the Approval Principles) underpin NPAS. The Approval Principles set the categories of accredited pathology laboratories, specify the standards to be met and the kind of pathology services provided.

The Approval Principles ensure that pathology practices providing Medicare eligible pathology services met and maintain compliance with the standards. The Approval Principles objectives include:

- supporting the diagnosis and treatment of illness by linking Medicare benefits to pathology services that provide reliable results
- reducing the risk of misdiagnosis from pathology services that provide unreliable results
- maintaining public confidence in pathology services.

The Commission administers the NPAS behalf of the Australian Government Department of Health, Disability and Ageing (the Department). The Department manages the policy and regulatory framework for pathology practice accreditation that are approved to provide Medicare eligible pathology services.

About the National Pathology Accreditation Advisory Council

The National Pathology Accreditation Advisory Council (NPAAC) was established in 1979 to consider and make recommendations to the Australian, state and territory governments on matters related to the accreditation of pathology practices and the introduction and maintenance of uniform standards of practice in pathology practices throughout Australia. NPAAC is responsible for formulating standards which pathology practices are assessed.

The Approval Principles give effect to NPAAC endorsed standards by listing the standards and accreditation materials pathology practices seeking approval to provide Medicare eligible pathology services must meet. The pathology practice's conformity with the standards is assessed by the accrediting agencies defined in the Approved Principles.

Introduction

The *Requirements for the Development and Use of In-house In Vitro Diagnostic Medical Devices (IVDs) (Fifth Edition, 2025)* is a Tier 3B NPAAC document. Together with the Requirements for Medical Pathology Services, it sets out the minimum requirements for best practice in the development and/or use of in-house IVDs.

Core principle

The fundamental principle of this document is that all in-house tests must be produced in a manner that ensures they are safe and perform as intended. This Standard supports that principle by introducing requirements for the design, production, verification, and validation of in-house IVDs.

Regulatory alignment

The document has been reviewed to reflect current regulatory requirements for in-house IVDs. These Requirements have been developed with reference to Australian legislation and international standards, including:

- **AS ISO 15189** – Medical laboratories – Requirements for quality and competence
- **ISO 13485** – Medical devices – Quality Management Systems – Requirements for Regulatory Purposes
- **ISO 14971** – Medical devices – Application of Risk Management to Medical Devices

Related documents and compliance

This document should be read within the national pathology accreditation framework, including current versions of the following NPAAC documents:

- All Tier 2 and Tier 3 documents
- Tier 4 documents, including:
 - Requirements for Laboratory Testing for Antibodies to HIV and HCV
 - Requirements for Medical Testing of Human Nucleic Acids
 - Requirements for Medical Testing of Microbial Nucleic Acids

Laboratories must also comply with relevant state and territory legislation, including any reporting requirements.

Document structure

Each section identifies key points for practice as either Standards (S) or Commentaries (C):

- **Standard:** The minimum requirement for procedures, methods, staffing, or facilities. Standards required before a laboratory can attain accreditation are prefaced with an 'S' (e.g., S2.2). The use of "must" indicates a mandatory requirement.
- **Commentary:** Provides clarification to the standards, examples, and guidance. Prefaced with a 'C' (e.g., C1.2), commentaries may be normative or informative. If a commentary uses "must," it is considered normative and holds the same weight as a Standard.

Appendices may also be normative or informative and are considered integral to the document.

Terminology

Accuracy

The closeness of the agreement between the result of a measurement and a true value of the [measurement](#)¹. If the true value cannot be determined, then an accepted value may be used as a substitute.

Adverse event

An event arising from the use of an IVD medical device that might lead, or might have led, to the death or serious deterioration in the state of health of a patient, a user of the IVD medical device or another person.

Analytical performance

The ability of an IVD medical device to detect or measure a particular analyte.

Clinical evidence for an IVD medical device

All the information that supports the scientific validity and performance for its use as intended by the manufacturer.

Clinical utility

The usefulness of the results obtained from testing with the IVD medical device and the value of the information to the individual being tested and/or the broader population.

Clinical performance

The ability of an IVD medical device to yield results that are correlated with a particular clinical condition/physiological state in accordance with the target population and the intended user.

¹ *International vocabulary of basic and general terms in Metrology (VIM) draft 2004 revision, definition 3.5*

Conformity assessment

Means a process undertaken by an accreditation body to assess the competence of a laboratory or organisation, based on particular Standard(s) and/or other normative documents, and for a [defined scope of accreditation](#).²

In vitro diagnostic medical device (IVD)

A device intended for the in-vitro examination of specimens derived from the human body, such as blood or tissue, to provide information on physiological or pathological states, health, or disease. ([TGA](#))

In-house IVD

The same as the definition in the [Therapeutic Goods \(Medical Devices\) Regulations 2002](#).¹ This an IVD medical device that is:

1. within the confines or scope of an Australian laboratory or Australian laboratory network:
 - a. developed from first principles; or
 - b. developed or modified from a published source; or
 - c. developed or modified from any other source; or
 - d. used for a purpose, other than the intended purpose assigned by the manufacturer; and
2. not supplied for use outside that laboratory or laboratory network.

Imprecision

The dispersion of independent results of measurements obtained under specified conditions. Imprecision is expressed numerically as standard deviation or coefficient of [variation](#).³

Note: The term 'imprecision' is used rather than 'precision' because the common measures used, such as standard deviation and coefficient of variation, are in fact measures of imprecision.

Intended purpose

The same as the definition in the [Therapeutic Goods \(Medical Devices\) Regulations 2002](#)¹ and is the purpose for which the manufacturer of the device intends it to be used, as stated in:

1. the information provided with the device; or
2. the instructions for use of the device; or
3. any advertising material applying to the device; and
4. technical documentation describing the mechanism of action of the device.

Medical laboratory network

A network of laboratory organisations that operate under a single Approved Pathology Authority (APA) with a single quality management system for which:

1. the activities of the network span more than one field of testing or program; or

² Derived from ISO/IEC 17011:2004 – *Conformity assessment - General requirements for accreditation bodies accrediting conformity assessment bodies*

³ Harmonized Terminology Database of the Clinical and Laboratory Sciences Institute

2. the network operates at multiple sites within a field or involves a combination of multiple sites and programs.

Method validation

The process of defining an analytical requirement and confirming that the method under consideration has performance capabilities consistent with that requirement.

Method verification

Procedures to test to what extent the performance data obtained by manufacturers during method validation can be reproduced in the environments of end-users.

Modified IVD

Any IVD medical device that is:

1. used for a purpose other than that intended by the original manufacturer; or
2. not used in accordance with the manufacturer's instructions for use or the methodology prescribed (i.e. modifications that could affect the performance of the device and would require validation).

Multivariate Index Assay (MIA)

An IVD medical device that:

1. combines the values of multiple variables using an interpretation function to yield a final, patient-specific result (such as a score or an index etc.) that is intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment or prevention of disease, and
2. provides a result whose derivation is non-transparent and cannot be independently derived or verified by the end user.

Scientific validity

The association of an analyte to a clinical condition / physiological state.

Context

In Australia, all in vitro diagnostic medical devices (IVD medical devices or IVDs) intended for therapeutic use are regulated under the Therapeutic Goods Act 1989.

A new regulatory framework for IVDs was implemented on 1 July 2010, following amendments to the Therapeutic Goods (Medical Devices) Regulations 2002 to include IVDs as a subset of medical devices.

Regulatory Requirements for IVDs

These legislative changes apply to all IVDs, including in-house IVDs, and require that all manufacturers certify their products as:

- Safe
- Fit for their intended purpose
- Manufactured to a high standard of quality

This is achieved by complying with a set of Essential Principles (EPs), which outline performance levels, hazards to be addressed, and issues to be considered. The EPs for safety and performance form the basis of the IVD regulatory framework and are set out in Schedule 1 of the Regulations.

Risk Classification of IVDs

The level of regulatory review required for each IVD is determined by assessing the risk posed to individual or public health. Classification rules consider the likelihood and severity of harm, assigning products to one of four risk categories:

- Class 1 IVD – No public health risk or low personal risk
- Class 2 IVD – Low public health risk or moderate personal risk
- Class 3 IVD – Moderate public health risk or high personal risk
- Class 4 IVD – High public health risk

Manufacturer Responsibilities

It is the manufacturer's responsibility to determine the classification of each IVD, based on its intended use and the significance of the result. These rules apply to both commercially supplied and in-house IVDs. If more than one classification rule applies, the IVD must be assigned the highest applicable classification.

Conformity Assessment Procedures

The classification of an IVD determines the minimum conformity assessment procedures required to demonstrate compliance with the Essential Principles (EPs). These procedures differ depending on whether the IVD is commercially supplied or manufactured in-house.

More detailed information is available in the guidance document [Classification of IVD Medical Devices](#) on the Therapeutic Goods Administration (TGA) website.

In Australia, all in vitro diagnostic medical devices (IVD medical devices or IVDs) that are intended to be used for a therapeutic purpose are subject to regulation under the *Therapeutic Goods Act 1989*. A new regulatory framework for IVDs was implemented on 1 July 2010, following amendments to the [Therapeutic Goods \(Medical Devices\) Regulations 2002](#)⁴¹ (the Regulations) to include IVDs as a subset of medical devices.

The changes made to the legislation apply to all IVDs, including in-house IVDs, and require that all manufacturers of IVDs certify that their products are safe, perform appropriately for their intended purpose, and are manufactured to a high standard of quality. This is achieved by complying with a set of Essential Principles (EPs) which identify performance levels required, hazards to be addressed, or issues to be considered. The EP for safety and performance form the basis of the IVD regulatory framework and are set out in Schedule 1 of the [Regulations](#).⁴¹

The degree of regulatory review each IVD is required to undergo is determined by assessing the risk posed to the health of the individual or to the public through use of that IVD. By applying a set of classification rules that consider the likelihood of harm and the severity of that harm, products are assigned to one of four risk categories:

- Class 1 IVD – No public health risk or low personal risk
- Class 2 IVD – Low public health risk or moderate personal risk
- Class 3 IVD – Moderate public health risk or high personal risk
- Class 4 IVD – High public health risk

The classification rules for IVDs are detailed in Schedule 2A of the [Regulations](#).⁴¹ It is the manufacturer's responsibility to determine the classification of each IVD and consideration must be given to its intended use and the overall significance of the final result. The classification rules are relevant to both commercially supplied and in-house IVDs, and except in those cases where a special rule exists, if more than one classification rule applies the IVD must assume the highest classification level.

The classification of the IVD will determine the minimum conformity assessment procedure(s) that a manufacturer must apply to demonstrate compliance with the EP. The appropriate conformity assessment procedure is further established based on either commercial or in-house manufacture. More detailed information relating to classification of IVDs is available in the guidance document *Classification of IVD Medical Devices* available on the [TGA website](#).⁵²

⁴ *Therapeutic Goods (Medical Devices) Regulations 2002*¹

⁵ *TGA Classification of IVD medical devices*²

In-house IVDs

In-house IVDs are separated into two groups for the purposes of determining the appropriate conformity assessment procedure:

- Class 1–3 in-house IVDs
- Class 4 in-house IVDs.

Manufacturers of in-house IVDs that are classified as a Class 1 in-house IVD, Class 2 in-house IVD or Class 3 in-house IVD are required to follow the set of conformity assessment procedures detailed in Schedule 3 Part 6A of the Regulations, and as outlined in the guidance document [The Regulatory Requirements for In-House IVDs in Australia](#).⁶³

Responsibility for review of each laboratory's compliance with the requirements rests principally with NATA and will be carried out in conjunction with their routine laboratory accreditation visits.

Class 1-3 in-house IVDs are exempt from inclusion in the ARTG subject to certain conditions:

- Laboratories manufacturing in-house IVDs are required to notify the TGA by 1 July 2017 of all in-house IVDs manufactured. After 1 July 2017 laboratories are required to re-notify the TGA only when new in-house IVDs are introduced (by 1 July of the next financial year). The details will be maintained by the TGA in a repository.
- Laboratories manufacturing in-house IVDs must be accredited as a medical testing laboratory and must meet *AS ISO 15189 Medical laboratories – Requirements for quality and competence*. NATA may be able to assess certain laboratories (that are outside the scope of ISO 15189) that manufacture Class 1-3 in-house IVDs against ISO/IEC 17025, *General requirement for the competence of testing and calibration laboratories*. Requests for assessment against ISO/IEC 17025 will be considered by NATA on a case-by-case basis and only in exceptional circumstances (e.g. veterinary laboratories that primarily perform testing on animals but may also perform testing on human samples on request).
- A laboratory that manufactures (or develops) in-house IVDs must meet the NPAAC Requirements for the Development and Use of In-house In Vitro Diagnostic Medical Devices (IVDs).
- Laboratories must maintain suitable documentation that can be used to demonstrate that each in-house IVD complies with the applicable provisions of the NPAAC Standards, including the *Requirements for Medical Pathology Services*. Information must include details of the design, development, production, validation and monitoring for each device.
- Laboratories must maintain a post-marketing system that monitors the performance of each in-house IVD, implements corrective action as appropriate to address deficiencies in design and production, and notify the TGA of any adverse events arising from the use of the in-house IVD.

Laboratories that manufacture Class 4 in-house IVDs need to include these in the ARTG, unless otherwise exempt. To do this, laboratories have a choice of two pathways:

- obtaining TGA conformity assessment certificates prior to applying for inclusion of their Class 4 in-house IVDs in the ARTG; or
- using their existing NATA accreditation to ISO 15189, or their TGA manufacturing licence, to apply directly for inclusion of their Class 4 in-house IVD in the ARTG.

⁶ *The Regulatory Requirements for In-House IVDs in Australia*³

Further information about conformity assessment procedures for Class 4 in-house IVDs is available on the TGA website.

Criteria for assessment of in-house IVDs

Standards outlined in this document, used for the assessment of in-house IVDs, have been separated into 11 sections:

1. general requirements
2. design
3. production and contracted services
4. analytical performance
5. scientific validity
6. clinical performance
7. clinical utility
8. companion diagnostics
9. monitoring, analysis and improvement
10. adverse events and recalls
11. documentation.

The requirements outlined in Sections 2 to 11 are intended to ensure that the quality system implemented by all accredited laboratories under AS ISO 15189, extends to the requirements surrounding the production or manufacture of an in-house IVD.

Laboratories that design, produce, and use in-house IVDs need to ensure that their current Quality System (QS) covers these requirements. The extra requirements of the QS to cover activities surrounding in-house IVDs may be summarised as:

- management responsibility
- resource management
- planning and production
- monitoring, analysis and improvement.

It is expected that most of these requirements will be met by modification of the existing QS within the laboratory. Extension of the QS requirements to cover in-house IVDs is considered in Section 2 to Section 11.

Standards

1. General requirements

No.	Standard and commentary
S1.1	The work environment must be conducive to ensuring that the design, production, and utilisation of in-house IVDs meet the regulatory requirements of this document.
S1.2	An in-house IVD must not be used in the provision of any service by a laboratory unless it has been validated according to these Requirements (except as outlined in S1.3 below).
C1.2 a	In-house IVDs, or commercial tests endorsed by the manufacturer as 'for research use only' or 'not for diagnostic use', or elements of such tests that are supplied as 'analyte-specific reagents' must be validated in accordance with this document if they are to be used in the management of a specific patient, or used to produce a result on a specific patient that may be used for patient management.
C1.2 b	An IVD is considered to be for research use only when the results produced using that IVD are neither used for nor intended to be used for patient management.

No.	Standard and commentary
S1.3	<p>If an in-house IVD cannot be fully validated, and there is no reasonable access to an alternative validated assay, and it is used in one or more of the circumstances described in C1.3a, then the report issued with the test result must contain the following statement:</p> <p><i>“The test used cannot be fully validated to the current NPAAC Requirements because (insert a brief reason) and the results should be interpreted accordingly. For further information please contact the laboratory.”</i></p>
C1.3 a	<p>Incompletely validated in-house IVDs must only be used clinically in the following circumstances:</p> <ul style="list-style-type: none"> <li data-bbox="533 763 1385 824">i. for a new or uncommon condition where its rarity precludes the laboratory from fulfilling all validation requirements <li data-bbox="533 857 1385 918">ii. an uncommon application where it is not possible to fulfil all validation requirements <li data-bbox="533 952 1385 1014">iii. a matter of urgency for a disease that poses a serious risk to public health.
C1.3 b	The laboratory must have a documented plan for validation.
C1.3 c	Where an in-house IVD has been used in the circumstances described in S1.3, validation records must be available to the fullest possible extent.
C1.3 d	Where an in-house IVD has been used in the circumstances described in C1.3a, validation must be completed as soon as possible.
S1.4	<p>If any modification is made to a commercially supplied IVD or an existing in-house IVD, it must be treated as a new in-house IVD, and the modification must be validated in accordance with these Requirements.</p>
C1.4 a	This must include changes to intended use (including sample type) or indications for use.
C1.4 b	Where an IVD has been modified, the validation steps required are determined by the nature of the modification. It must be demonstrated that the changes have been properly assessed and show that the assay continues to perform safely and effectively.

No. Standard and commentary

- S1.5 Where a laboratory develops an in-house IVD, that IVD must only be used in that laboratory or its own laboratory network.
- C1.5 a If a laboratory supplies an in-house IVD that has been manufactured in-house to a laboratory outside of its own laboratory network, then that IVD must be assessed as a commercially supplied IVD, and as such, must meet the requirements for commercially supplied IVDs as set out in the [Therapeutic Goods \(Medical Devices\) Regulations 2002](#).⁷¹
- C1.5 b This Standard does not prevent collaboration in the design and development of IVDs or exchange of clinical samples as these are not captured by the definition of an in-house IVD.
-

⁷ Therapeutic Goods (Medical Devices) Regulations 2002¹

2. Design

No.	Standard and commentary
S2.1	The laboratory must have and maintain a QS that ensures that all phases in the design, production, utilisation, storage, packaging and transport of in-house IVDs within the laboratory are sufficient and fully documented to ensure that any in-house IVD produced is suitable for purpose.
C2.1 a	For each in-house IVD, there should be a file containing documents defining IVD specifications, production processes and QS requirements.
S2.2	The IVD must be designed and produced so that when used under the conditions and for the purposes intended, all reasonable measures have been taken to minimise the risk of compromising the health and safety of the patient, the user or any other person.
S2.3	The design and construction of the IVD must conform to the Essential Principles ¹ , (refer to Appendix A) and consider best practice, where this includes identifying and eliminating risks associated with use (including disposal), and ensuring that adequate protection measures are in place.
C2.3 a	The laboratory must ensure that the safety of the patient, the operator, and other staff is not compromised by the design, production, or the use of the validated IVD, through compliance with all state and territory occupational health and safety requirements.

No.	Standard and commentary
C2.3 b	ISO 14971 Medical Devices - <i>Application of Risk Management to Medical Devices</i> . Annex H: Guidance on risk management for in vitro diagnostic devices provides useful information on identification, evaluation and control of risk.
S2.4	The IVD must be designed and produced in a way that ensures it is safe to use for the entire intended life of the device.
S2.5	Where parts of the in-house IVD are to be purchased from an external source, the laboratory must ensure that the products purchased will meet the requirements as specified in the design protocol.

3. Production and contracted services

Planning, scheduling resources, and purchasing are all part of the manufacture of in-house IVDs as are procedures for monitoring these processes.

No.	Standard and commentary
S3.1	The laboratory must establish documented procedures to ensure that products sourced for use in the routine production of in-house IVDs conform to specified requirements and are traceable.
S3.2	The laboratory must ensure that sub-contracted services that affect the in-house IVD are controlled.
S3.3	Where work environment conditions are critical for the development, production, validation, or use of the in-house IVD, the laboratory must monitor and control these work environment conditions.
S3.4	Senior staff must have significant diagnostic or research experience with new test development and validation. The depth and complexity of this experience must be commensurate with the range and complexity of IVD development undertaken in the laboratory.
C3.4 a	The presence of experienced supervisors and trainers is essential, given their critical involvement in error detection, error correction and problem solving.
S3.5	The laboratory must plan and carry out the production of in-house IVDs under controlled conditions from design, manufacture and validation of the proposed product to its release for routine use.

No. Standard and commentary

- C3.5 a Controlled conditions include:
- i. identification of different stages of assay development, including routine production
 - ii. implementation of review, verification and validation of the above by designated personnel
 - iii. documented requirements (e.g. batch size, acceptable performance limits)
 - iv. identification and use of reference materials and reference measurement procedures
 - v. identification and use of suitable equipment (i.e. appropriate for use and calibrated)
 - vi. identification and use of monitoring and measuring processes and devices
 - vii. planned and documented specifications and processes for the release of the product, and for the receipt of the product at the site of routine storage before product use
 - viii. planned and documented specifications and processes for any packaging and labelling of the final product, accessories or components
 - ix. planned and documented specifications, processes and records if cleanliness of the environment is critical (e.g. production step where sterilisation is required).

-
- S3.6 The laboratory must establish procedures to verify the suitability of the in-house IVD for use in the setting in which it will normally be used.
-

No. Standard and commentary

- S3.7 Records relating to production batches and the status of an in-house IVD, or a component thereof, must be traceable and retained for a minimum of 4 years beyond the date of their valid use or 5 years from the date of manufacture and:
- a. the laboratory must maintain records of each batch produced. This must include records of all components of the batch, and any other information relevant to the successful use of the batch in the routine environment.
 - b. each batch, and each component within the batch, must be assigned a unique identifier and must be available for the purposes of traceability.
 - c. at each stage of production, the product status must be identifiable. A batch of an in-house IVD awaiting final release validation must be clearly identified as such. A batch that has been deemed acceptable for routine use (i.e. validation criteria have been passed) should be identified as such.
 - d. if a component within a batch is changed, then that batch must be considered as a new batch and will require re-validation.
-
- S3.8 The laboratory must establish documented procedures to ensure that conditions preserving the effectiveness of an in-house IVD are not compromised.
-
- S3.9 The laboratory must ensure that any validation and monitoring measures required for verification of the processing steps are identified, validated and documented.
-
- S3.10 If a batch, or part thereof, is distributed within a laboratory network, then procedures or instructions must also be issued relating to the transport, receipt and use of the test at its destination. Such instructions should refer to the packaging, transport, handling, storage and identification of the in-house IVD.
-

4. Analytical performance

The analytical performance of an in-house IVD medical device is its ability to detect or measure a particular analyte.

No.	Standard and commentary
S4.1	The stability of the analyte being measured must be determined under the sample storage conditions being used.
S4.2	The suitability of an IVD must be demonstrated for use with each specimen type to be tested under the collection and transport conditions used by the laboratory.
S4.3	The minimum specimen handling and IVD storage conditions must be determined and documented for the end-users of the in-house IVD.
S4.4	The accuracy and imprecision of in-house IVDs must be determined by at least one of the following methods applicable to the relevant biological material: <ol style="list-style-type: none">The use of certified reference materialComparison with a definitive method or a reference methodPerformance of recovery experimentsUse of validated in-house reference materialPerformance in external proficiency-testing programs or laboratory sample exchange programs.

No.	Standard and commentary
C4.4 a	The materials used in this analysis may include known positive and negative control samples or proficiency material or be from patients of known clinical states. The threshold for detection of an analyte can be determined by the repeat analysis of samples with results near the cut-off of sensitivity for the IVDs.
S4.5	Sufficient numbers of specimens and appropriate statistical tools must be employed in the development phase to achieve the confidence levels required to satisfy both the analytical performance and the required clinical utility of the test.
C4.5 a	In general, validation of analytical performance requires that the reference interval, analytical sensitivity, limits of detection, analytical specificity, accuracy, imprecision, linearity, and freedom from interference be addressed. Laboratories should strive to achieve the best test performance relevant to the intended clinical use of the IVD.
C4.5 b	It is not possible to be prescriptive about the required sensitivity and specificity, nor about the number of specimens involved, because these will vary with the intended use and with the significance of false results. Where there are significant guidelines available, these should be taken into consideration when assessing IVD performance. An example of this would be use of the PHLN guidelines for gonococcal PCR ⁴ .
C4.5 c	Consideration should be given to seeking statistical advice if required.
S4.6	The source and number of specimens tested during the validation phase must be documented.
C4.6 a	Relevant legislative and organisational policies on the use of clinical samples for validation purposes must be followed.
S4.7	An estimate of measurement uncertainty of the in-house IVD must be determined where relevant and possible.
S4.8	The detectable and measurable range and limit of detection of the IVD must be determined where it yields a quantitative or, where appropriate, a semi-quantitative result.

No.	Standard and commentary
C4.8 a	In general, validation of quantitative, semi-quantitative and qualitative IVD procedures should include a comparative evaluation of the IVD against the definitive method, a reference method, or an established procedure with known analytical performance and clinical utility. Where there are discrepancies between the new in-house IVD and its comparator, then an analysis of discrepant results should be performed using other test modalities, review of clinical and other information, and/or referral to another laboratory for testing.
C4.8 b	Cut-off values for determination of positivity and/or negativity should be derived for an IVD where it yields a semi-quantitative or qualitative result.
C4.8 c	Where appropriate, it should be demonstrated that IVDs for genetic tests are capable of distinguishing between homozygotes, heterozygotes and hemizygotes for the alleles in question.
S4.9	There must be an investigation to detect possible interference of performance of the IVD, where applicable. The laboratory must be able to show that at least the most likely interfering substances have been eliminated as a source of error.
C4.9 a	It is important to know whether the IVD responds uniquely to the analyte that it was designed to measure or detect, or whether there are any other analytes that may also react with the test system to give unexpected or invalid results. This is particularly important in nucleic acid amplification for viral or bacterial markers, where highly conserved areas of DNA may cross many species boundaries.
S4.10	Measurement of robustness must be performed by determining the impact of expected changes in conditions.
C4.10 a	Expected changes may include operator, equipment (where more than one instrument may be used), different source of reagent, or changes in parameters such as pH, temperature and/or humidity. This is particularly important where the in-house IVD is distributed within a laboratory network. Measurement can be done by use of controls and an evaluation panel that best tests the critical components of technical performance, particularly the sensitivity and specificity of the test.
S4.11	Reagent stability must be monitored and recorded over time, and comparable performance of the IVD from batch to batch must be demonstrated. Expiry dates, if relevant, must be documented.
C4.11 a	The internal QC and/or external proficiency testing programs will assist with this process.

No.	Standard and commentary
S4.12	Equipment must be used in its intended manner or, the performance of the equipment must be verified as part of the in-house IVD validation.
S4.13	Laboratories must verify the performance of their in-house IVDs for the intended specimen types and conditions.
C4.13 a	Types of specimens used for validation should be as similar as possible to the specimens expected to be routinely received for testing.
C4.13 b	Specimens should also be chosen to yield results that cover at least the range of possible results expected from patient samples.
S4.14	Laboratories must determine appropriate specimen handling, storage conditions, and specimen types, where applicable, and inform collection staff and staff performing the medical testing with the in-house IVD of these limitations.

5. Scientific validity

The scientific validity of an analyte is the association of that analyte with a clinical condition or physiological state.

Scientific validity is often identified from academic research and is supported by studies evaluating the analyte for potential clinical applications. The generation and assessment of clinical evidence is an ongoing process. Information related to clinical evidence should be monitored routinely once the in-house IVD is being used for patient testing by the laboratory.

No.	Standard and commentary
S5.1	A clinically useful association between the clinical condition and the interpretation of the in house IVD must be demonstrated. Level 1 or Level 2 published evidence must be cited based on either NHMRC ⁵ , EGAPP ⁶ , Eurogentest Gene cards ⁷ or other guidelines for the evaluation of such evidence.
C5.1 a	A single retrospective study or a case-control study (evidence Level 3), whilst important in establishing proof of concept should not necessarily be considered sufficient to clinically validate a new biomarker assay.
S5.2	Requirements of clinicians and other relevant parties, including their expectations relating to the level of service and the type and extent of interpretation, must be considered when designing an in-house IVD.

6. Clinical performance

The clinical performance of an in-house IVD medical device is its ability to yield results that are correlated with a particular clinical condition/ physiological state according to a target population and an intended user.

No.	Standard and commentary
S6.1	The clinical sensitivity and specificity as well as positive and negative predictive values must be available for the relevant condition.
C6.1 a	Such data can be derived from multiple sources such as clinical performance studies, published studies from other groups, or experience gained by routine diagnostic testing.
C6.1 b	Further information on clinical performance study design may be found in the GHTF document GHTF/SG5/N8:2012 entitled Clinical Evidence for IVD medical Devices – Clinical Performance Studies for In Vitro Diagnostic Medical Devices . ⁸

⁸ please note that GHTF documents are now published through the *International Medical device Regulators Forum* which can be found on [International Medical Device Regulators Forum](#)

7. Clinical utility

The clinical utility of any new in-house IVD medical device is the usefulness of results obtained from testing with the IVD and the value of the information to the individual being tested and/or the broader population.

No.	Standard and commentary
S7.1	New in-house IVDs for novel tests, or established IVDs for a novel use, must only be offered in the clinical setting (as opposed to the research setting) where there is sufficient evidence of clinical utility for the specific population of patients in which the assay is intended for use.
C7.1 a	Levels of evidence must be assessed in accordance with relevant criteria, such as NHMRC ⁵ , EGAPP ⁶ , Eurogentest Clinical Utility Gene Cards ⁷ , or other guidelines for evaluating such evidence. The source of the criteria must be cited.
C7.1 b	The pre-test probability of a positive or negative result—and the risks associated with false positive or false negative results—can vary significantly between populations (e.g. symptomatic vs asymptomatic patients).
C7.1 c	Assessment of evidence for clinical utility should focus on: <ul style="list-style-type: none"><li data-bbox="485 1704 1390 1760">i. supporting data from clinicians explaining why the test is needed and how it will be used in clinical decision-making.<li data-bbox="485 1794 1342 1850">ii. the quality of individual studies, the overall body of evidence, and the quantity of relevant data.<li data-bbox="485 1883 1161 1921">iii. the consistency and generalisability of findings.

No. Standard and commentary

S7.2 The introduction of an in-house IVD must be a planned activity designed to produce a test that is fit for purpose in terms of clinical performance and clinical utility. The laboratory must demonstrate that the product's design and development process was directed towards meeting these criteria.

C7.2 a Relevant considerations may include:

- I. the prevalence of the clinical condition.
- II. the expected number and frequency of referrals
- III. the need for out-of-hours testing
- IV. whether a reference laboratory service is required
- V. whether a lower level of service is sufficient.

Example: A qualitative assay for BCR–ABL mRNA may be suitable for diagnosing chronic myeloid leukaemia, while a quantitative assay is needed for monitoring residual disease.

8. Companion diagnostics

A companion diagnostic IVD provides essential information for the safe and effective use of a medicine or biological product.

For a device to be considered a companion diagnostic, the medicine must be approved in Australia and include within its product information that companion testing is essential for the safe and effective use for the relevant medicine or biological product. The TGA's [Understanding regulatory requirements for in vitro diagnostic \(IVD\) companion diagnostics \(CDx\)](#) provides further information on companion diagnostics.

No.	Standard and commentary
S8.1	Companion diagnostics that have not been approved for diagnostic use by the TGA must be considered an in-house IVD for the matching medicine or biological product and evaluated in accordance with these requirements before being used for diagnostic or therapeutic purposes.
C8.1 a	The intended purpose of a companion diagnostic must clearly state that it is to be used for one or both of the following, where the product information for the medicine or biological states that companion testing is essential for: <ul style="list-style-type: none"><li data-bbox="485 1576 1331 1637">i. selecting patients for treatment with a medicine or biological product.<li data-bbox="485 1671 1362 1733">ii. monitoring patients who are being treated with the medicine or biological product.
C8.1 b	An in-house IVD must not include, in its intended purpose or patient reports any recommendation for the use of a specific medicine or biological product unless it has been validated as a companion diagnostic.

No. Standard and commentary

- C8.1 c The clinical utility of a companion diagnostic is demonstrated by one or more pivotal clinical studies (the clinical trial assay) that align with the TGA's approval of the medicine or biological product.
- C8.1 d Where a pathology laboratory is seeking accreditation of a companion diagnostic, but the in-house IVD was not the IVD used in the pivotal studies, the laboratory must demonstrate clinical utility by showing clinical comparability to the clinical trial assay. The process includes:
- i. a direct clinical comparability study conducted on samples from the pivotal clinical study; or
 - ii. a direct clinical comparability study conducted on samples from patients like those enrolled in the pivotal clinical study; or
 - iii. an indirect clinical comparability where there is:
 - a) strong evidence that the scientific validity, analytical and clinical performance of the companion diagnostic is highly comparable to the clinical trial assay
 - b) a scientific and clinical justification that the companion diagnostic will deliver clinically comparable outcomes to those in the pivotal clinical study and therefore a clinical comparability study is not required.

Direct clinical comparability example

When no 'gold standard' biomarker exists, a clinical comparability study may be conducted using samples from the pivotal study or similar patients, comparing the in-house IVD to the clinical trial assay or a validated equivalent.

Indirect clinical comparability example

When the in-house IVD detects the same biomarker in samples similar to those used in the clinical trial, with comparable analytical performance and within an accredited external quality assessment program, clinical comparability may be inferred.

9. Multivariate index assays

A Multivariate Index Assay (MIA) is an IVD medical device that:

- a. combines the values of multiple variables using an interpretation function to yield a final, patient-specific result (such as a score or an index etc.) that is intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment or prevention of disease, and
- b. provides a result whose derivation is non-transparent and cannot be independently derived or verified by the end user.

In other words, the requesting clinician requires information from the test developer, rather than generally accepted information from the clinical community, to interpret the MIA result for use in patient management.

No.	Standard and commentary
S9.1	Multivariate Index Assays that have not been approved for diagnostic use by the TGA (or are sold as RUO) must be considered an in-house IVD and evaluated in accordance with these Requirements before being used for diagnostic or therapeutic purposes.
C9.1 a	In particular, validation, verification and documentation of the algorithm in relation to clinical utility of the assay must be subject to the same level of rigor as other analytical aspects of the assay.

10. Monitoring, analysis and improvement

Monitoring the performance of in-house IVDs and the analysis of such monitoring is to ensure that there are processes in place to demonstrate the conformity of the IVD (i.e. its suitability for purpose).

The laboratory should be able to identify and implement any changes necessary to maintain the quality and suitability of the IVD for its intended purpose, and to ensure continued suitability and effectiveness.

No.	Standard and commentary
S10.1	Previously defined and documented performance characteristics of the IVD must be monitored and measured to verify that product requirements have been met.
C10.1 a	Where laboratories generate their own in-house quality control material then such material is also an in-house IVD and must be validated as such and must also be included on the TGA in-house IVD notification database.
C10.1 b	Where available, laboratories should use well-characterised and standardised control material that is available to a range of laboratories. However, if necessary, laboratories may generate their own quality control material. If so, they must verify stability of such material under the storage and any inter-laboratory transport conditions used.
C10.1 c	Where possible, preventive action should be taken to eliminate causes of potential non-conformities to prevent their occurrence, as identified through the risk analysis undertaken during the design phase of the IVD.
S10.2	The organisation must establish documented procedures to analyse appropriate data to demonstrate the conformity of the in-house IVD to product specifications.

No. Standard and commentary

C10.2 a Data should be sourced from multiple sources such as internal audits, user feedback, nonconformity to internal QC or external quality assurance, and feedback from suppliers on specific reagents or products incorporated into the in-house IVD.

11. Adverse events and recalls

The act of reporting information about an adverse event is not an admission of liability for the event or its consequences. Examples of adverse events and requirements are outlined in Table 1.

No.	Standard and commentary
S11.1	Information about an adverse event resulting from the use of an in-house IVD, must be reported to the laboratory's designated person and to the Therapeutic Goods Administration (TGA) as soon as practicable but within the timeframes specified.
C11.1 a	Laboratories must have documented procedures for reporting adverse events to the designated person and the TGA.
C11.1 b	Information about an adverse event that presents a serious public health threat or concern must be reported to the TGA within 48 hours of the laboratory becoming aware of the event.
C11.1 c	Information about an adverse event that led to the death or serious deterioration in the state of health of a patient, a user of the in-house IVD or another person must be reported to the TGA within 10 days of the laboratory becoming aware of the event.
C11.1 d	Information about an adverse event that might lead to the death or serious deterioration in the state of health of a patient, a user of the in-house IVD or another person must be reported to the TGA within 30 days of the laboratory becoming aware of the event.

No. Standard and commentary

- C11.1 e Adverse events may arise from malfunction or deterioration in the characteristics or performance of the in-house IVD, inadequacy in the design, production, labelling or instructions for use of the in-house IVD, or use of the in-house IVD that is contrary to the intended use.
- C11.1 f Adverse events that lead to a serious deterioration in the state of health of a patient, a user of the in-house IVD or another person include:
- i. a life-threatening illness or injury
 - ii. permanent impairment of a body function
 - iii. permanent damage to a body structure
 - iv. a condition necessitating medical or surgical intervention to prevent permanent impairment of a body function or permanent damage to a body structure.
- C11.1 g Adverse events include ‘near misses’ that did not result in any harm but might have led to the death or serious deterioration in the health of a patient or user of an in-house IVD on another occasion.
- C11.1 h Reporting of information about adverse events to the TGA should occur through the [Medical Device Incident Report Investigation Scheme \(IRIS\)](#)⁸.
- C11.1 i Reporting of information about adverse patient outcomes to the TGA is not required where the adverse outcome resulted from known limitations in the design of the in-house IVD and the in-house IVD performed within its accepted design parameters, for example
- i. A false negative result leads to a patient not being treated.
 - ii. The analytical sensitivity of the in-house IVD is known to be 95% and is clearly stated in the instructions for use/method.
 - iii. The in-house IVD was performing within its design parameters, as evidence by results of positive controls performed with the patient’s sample.

Although not initially considered an adverse event that requires reporting to TGA, such incidents must be recorded and monitored by the laboratory (as per S10.2) to ensure the in-house IVD is operating within expected limitations. Multiple incidences may identify a problem with an in-house IVD that subsequently could require reporting to the TGA as an adverse event.

No. Standard and commentary

C11.1 j	All adverse event reporting procedures must be documented in the quality management system.
S11.2 Recalls	A laboratory must report to its designated person and the TGA, information relating to any malfunction or deterioration of a Class 4 in-house IVD, or inadequacy in its design, production, labelling or instructions for use, that has led the laboratory to take steps to recover devices of that kind that have been distributed for use in that laboratory or other laboratories within that laboratory network.
C11.2 a	Laboratories must have documented procedures in place for reporting any such recalls for Class 4 in-house IVDs to its designated person and the TGA.
C11.2 b	Reporting of recalls to the TGA Recalls Unit can be made by mail, fax or email and should be done in accordance with the requirements of Uniform Recall Procedure for Therapeutic Goods (URPTG). Contact information for the Recalls Unit can be found on the Procedure for recalls, product alerts and product corrections (PRAC) Therapeutic Goods Administration (TGA) ⁹ .

Table 1 Examples of adverse events and requirements

Adverse event	Requirement
A false negative result associated with the malfunction of an in-house IVD that presents a serious public health threat (e.g. false negative HIV donor screening result due to a malfunction of the in-house IVD).	Report to TGA within 48 hours of the laboratory becoming aware of the event.
A false negative result associated with the deterioration in the performance of an in-house IVD that has led to the death or serious deterioration in the state of health of a patient (e.g. false negative result for bacterial meningitis due to deterioration in the sensitivity of the in-house IVD).	Report to TGA within 10 days of the laboratory becoming aware of the event
A false negative or false positive result associated with an inadequacy in the design or manufacture of an in-house IVD which might lead to the death or serious deterioration in the health of a patient (e.g. incorrect genotype identification due to an inadequacy in the design of the in-house IVD that has resulted in inappropriate patient treatment).	Report to TGA within 30 days of the laboratory becoming aware of the event

⁹ Therapeutic Goods Administration. *Procedure for recalls, product alerts and product corrections (PRAC)* [Internet]. Canberra (AU): TGA; 2026 Feb 24 [updated 2026 Feb 24]. Available from: <https://www.tga.gov.au/safety/recalls-and-other-market-actions/procedure-recalls-product-alerts-and-product-corrections-prac>

12. Documentation

No.	Standard and commentary
-----	-------------------------

S12.1	The laboratory must establish documented procedures for the design, development, production, validation and monitoring of an in-house IVD.
-------	--

C12.1 a	This documentation on method establishment:
---------	---

	a. must include where relevant:
--	---------------------------------

- | | |
|--|---|
| | i. description of the analytical method |
| | ii. selection criteria for reagents and their source(s) |
| | iii. quality and identity of standards used |
| | iv. description of experiments to determine accuracy, imprecision and any other performance characteristics |
| | v. an estimate of measurement uncertainty |
| | vi. description of stability studies |
| | vii. information on sample processing and storage |
| | viii. summary tables of analytical runs, including any method deviations |
| | ix. any calculations applied to results |
| | x. summary information on QC samples |
| | xi. post-implementation monitoring and improvement |

No. Standard and commentary

- xii. the use of assays for non-validated criteria
 - xiii. any other relevant information relating to the assay
 - b. may include where relevant:
 - i. criteria for acceptance or rejection of the standard or calibration curve
 - ii. criteria for acceptance or rejection of QC
 - iii. criteria for variability of duplicate assays.

- C12.1 b The laboratory must produce a report on method validation that shows the successful completion of appropriate validation studies for the in-house IVD in question.

 The method-validation report must include:
 - i. summary information
 - ii. method development and establishment
 - iii. risk analysis
 - iv. application of the method to routine sample analysis
 - v. management approval for implementation
 - vi. references
 - vii. other relevant information.

- C12.1 c Documentation relating to design, development and validation must be retained for a period of not less than 4 years after cessation of use of the in-house IVD.

- C12.1 d The summary should list all method-validation studies, verification and revalidation signed by a Laboratory Director or delegate. Any changes to the method over time, including subsequent revalidation and verification, should be added to the summary report.

- C12.1 e Where full validation data is not readily accessible for in-house IVDs produced before the NPAAC Requirements for the Development and Use of In-House IVDs (Second Edition 2007), evidence to support the analytical and clinical performance of an in-house IVD may be provided in the form of ongoing monitoring and surveillance, which may include historical EQA data, QC reports or clinical correlation.

No. Standard and commentary

- C12.1 f It is recommended that the following data should be added to the validation file over time:
- i. QC monitoring of sensitivity and specificity
 - ii. uncharacteristic changes to detection limits.
-

Appendices

Appendix A: Essential Principles

Normative

The Essential Principles are set out in Schedule 1 of the [Therapeutic Goods \(Medical Devices\) Regulations 2002](#) and provide information about the safety and performance levels required, hazards to be addressed, or issues to be considered when manufacturing medical devices. Readers are encouraged to review the current Regulations from the Federal Register of Legislation noting that the legislation may be subject to amendment from time to time.

Appendix B: Classification rules for IVDs

Normative

The classification rules applicable for IVDs are located in Schedule 2A of the [Therapeutic Goods \(Medical Devices\) Regulations 2002](#), and set out the assigned risk classification for an IVD medical device. Readers are encouraged to review the current Regulations on the Federal Register of Legislation noting that the legislation may be subject to amendment from time to time.

Appendix C: Procedures applying to in-house IVD medical devices

Normative

The conformity assessment procedures in Schedule 3, Part 6A of the [Therapeutic Goods \(Medical Devices\) Regulations 2002](#) set out the minimum requirements to be met by laboratories manufacturing Class 1-3 in-house IVDs.

The conformity assessment procedures in Schedule 3, Part 6B of the [Therapeutic Goods \(Medical Devices\) Regulations 2002](#) set out the minimum requirements to be met by laboratories manufacturing Class 4 in-house IVDs. Alternatively, if preferred, laboratories that manufacture Class 4 in-house IVD have the choice of applying the conformity assessment procedures set out in Schedule 3, Part 1 of the [Therapeutic Goods \(Medical Devices\) Regulations 2002](#) (i.e. same conformity assessment procedures as those for manufacturers of commercially supplied IVDs).

A copy of the current Regulations that may be subject to change from time to time can be accessed from Federal Register of Legislation.

Appendix D: Frequently asked questions and examples for guidance

Informative

The following guidance is provided in response to frequently asked questions relating to in-house IVDs.

If a laboratory makes up its own culture media, are these in-house IVDs?

If a laboratory utilises their own formulation to make microbiological culture media from general laboratory reagents (e.g. dehydrated powders and agar bases) with the intention of using them for a diagnostic purpose, then they are considered Class 1 in-house IVDs.

If a laboratory makes up its own stains, are these in-house IVDs?

If a laboratory utilises their own formulation to make stains, dyes or other staining solutions (e.g. fixatives, decolourising agents) with the intention of using them for a diagnostic purpose, then those stains are considered in-house IVDs.

What are the requirements for validating stains that are prepared in-house?

The validation of staining solutions that have been prepared 'in-house' should consider the following aspects:

- Physical properties of the individual components used as well as the finished product (e.g. pH, ionic concentration, water quality – deionised/filtered).
- Testing of the finished stain using a range of specimens as appropriate to the stain type (tissue sections, organisms, control slides etc).
- The test slides should cover the range of features in tissue or cells that are expected to be seen under routine conditions of use.

When validating the performance of an in-house IVD, what constitutes statistically significance numbers?

Because circumstances can vary so much, even between similar IVDs, it is not possible to specify the minimum numbers of samples required to be tested in any situation, but ideally every effort should be made to make the evaluation of sensitivity and specificity of the assay statistically significant.

Each variable aspect of an assay which *may* have an impact on assay performance should be considered, including (but not limited to):

- The range and number of samples tested should be selected to cover the entire measuring range – i.e., the upper, middle lower concentrations of the target analyte, with consideration given to the upper and lower extremes for quantitative or semi-quantitative assays, or for qualitative assays the limit of detection (i.e., near cut off).
- Samples should be selected from a population range similar to the intended setting of use (adults, elderly, children, neonates, endemic persons (important for some infectious diseases)).
- The recommended specimen types (serum, plasma, urine, saliva etc), and storage stability; specimen characterisation should include enough samples to cover likely variants of the target analyte, including different serotypes, sub-types, weakly reacting specimens, or if there is more than one analyte, a number of mixed targets across the selection of specimens tested. If there is difficulty in availability of suitable specimens, every effort should be made to obtain them from alternative sources (other laboratories, commercially sourced specimens, spiked).
- A selection of samples representing similar or commonly cross-reacting clinical conditions or infectious diseases should be included.

What aspects of my in-house assay do I need to validate?

- The classification and intended purpose of the in-house IVD will determine depth of validation required and the aspects to be validated.
- An in-house IVD developed from first principles or developed (or modified) from a published source would require more validation than an in-house IVD based on changes made to a commercially supplied IVD.
- Where a commercially supplied IVD has been modified, validation should focus principally on the effects of that change.
- Factors to be considered include the target analyte of the IVD, whether it is a qualitative or quantitative assay, complexity of methodology, the availability and range of characterised samples, the availability of published (peer-reviewed) articles relating to that IVD or other similar IVDs. Each performance characteristic should be considered (as appropriate) and may include sensitivity and specificity (both analytical and clinical); accuracy (trueness); precision (reproducibility and repeatability); measuring range; linearity; and assay cut-off.

How are assays that are labelled research use only (RUO), including components such as primers or probes to be treated?

- If a laboratory is utilising primers and probes as components for use in an in-house IVD, or if they utilising a RUO marked kit which they intend to use for a diagnostic purpose (i.e. reporting of patient results) then the assay they have developed meets the definition of an in-house IVD and the laboratory is required to validate in accordance with this document.
- The suppliers of kits marked RUO should be aware that under the Therapeutic Goods Act, the definition of a therapeutic good includes *goods that are represented in any way to be, or that are, whether because of the way in which the goods are presented or for any other reason, likely to be taken to be for therapeutic use.*
- Representation for therapeutic use includes verbal or written statements made in relation to products as part of their labelling, advertising or promotion (regardless of the RUO label).

A laboratory performs flow cytometry on blood, bone marrow and tissue samples for the diagnosis of haematological malignancies. There is considerable heterogeneity between these malignancies and therefore the number of permutations for each panel of antibodies is considerable and is sample dependent. Does each panel of antibodies need to be validated and considered to be an in-house IVD?

- The test should be considered to be an in-house IVD for the identification of the most appropriate immunophenotype to assist with the accurate diagnosis of the malignancy. The in-house IVD may therefore be notified to the TGA as a single test “Immunophenotyping of haematological malignancy” and not as each component (e.g. CD3, CD19 etc). Validation should include the performance of each individual component singly and when used in a cocktail as well as the ability to accurately determine the immunophenotype.

References

1. **Federal Register of Legislation.** Therapeutic Goods (Medical Devices) Regulations 2002. Canberra (AU): Therapeutic Goods Administration; 2018 [cited 2026 Mar 21]. Available: <https://www.legislation.gov.au/F2002B00237/latest/text>
2. **Therapeutic Goods Administration.** Classification of IVD Medical Devices. Canberra (AU): TGA; 2015 [cited 2018 Jan 18]. Available: <https://www.tga.gov.au/publication/classification-ivd-medical-devices>
3. **Therapeutic Goods Administration.** Regulatory Requirements for In-house IVDs. Canberra (AU): TGA; 2017 [cited 2018 Jan 18]. Available: <https://www.tga.gov.au/sites/default/files/regulatory-requirements-in-house-ivds.pdf>
4. **Smith DW, Tapsall JW, Lum G.** Guidelines for the use and interpretation of nucleic acid detection tests for *Neisseria gonorrhoeae* in Australia. Canberra (AU): Public Health Laboratory Network; 2005 [cited 2018 Jan 30]. Available: <https://www.cdc.gov.au/resources/publications/phln-guidelines-nucleic-acid-tests-neisseria-gonorrhoeae>
5. **National Health and Medical Research Council.** National Statement on Ethical Conduct in Research Involving Humans. Canberra (AU): NHMRC; 2007, updated 2015 [cited 2018 Jan 18]. Available: <https://www.nhmrc.gov.au/guidelines-publications/e72>
6. **Teutsch SM, Bradley LA, Palomaki GE, et al.** The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. *Genet Med.* 2009 Jan;11(1):3-14. doi: 10.1097/gim.0b013e318184137c. PMID: 18813139; PMCID: PMC2743609. Available: <https://europepmc.org/articles/PMC2743609>
7. **Eurogentest.** Harmonizing Genetic Testing Across Europe. Leuven (BE): Eurogentest; 2011 [cited 2018 Jan 18]. Available: <http://www.eurogentest.org/web/info/public/unit3/geneCards.xhtml>
8. **Therapeutic Goods Administration.** Reporting Adverse Events. Canberra (AU): TGA; 2018 [cited 2018 Jan 18]. Available: <https://www.tga.gov.au/reporting-adverse-events>

Bibliography

British Standards Institute. *Stability testing for in vitro diagnostic reagents (EN 13640).*

London: BSI; 2002. Available from: <https://mdcpp.com/doc/standard/BSEN13640-2002.PDF>
[\[mdcpp.com\]](https://mdcpp.com)

Clinical and Laboratory Standards Institute. *EP17-A2: Evaluation of detection capability for clinical laboratory measurement procedures; approved guideline.* Pennsylvania: CLSI; 2012. Available: <https://clsi.org/shop/standards/ep17/> [\[clsi.org\]](https://clsi.org)

Clinical and Laboratory Standards Institute. *EP25-A: Evaluation of stability of in vitro diagnostic reagents; approved guideline.* Pennsylvania: CLSI; 2009. Available: <https://clsi.org/shop/standards/ep25/> [\[clsi.org\]](https://clsi.org)

Clinical and Laboratory Standards Institute. *Harmonized Terminology Database.* 2017 [cited 2018 Jan 12]. Available: <https://htd.clsi.org/> [\[htd.clsi.org\]](https://htd.clsi.org/)

Global Harmonization Task Force. *GHTF/SG5/N6:2012 – Clinical evidence for IVD medical devices: key definitions and concepts.* 2012. Available: <https://www.imdrf.org/sites/default/files/docs/ghtf/final/sg5/technical-docs/ghtf-sg5-n6-2012-clinical-evidence-ivd-medical-devices-121102.pdf> [\[imdrf.org\]](https://www.imdrf.org)

Global Harmonization Task Force. *GHTF/SG5/N7:2012 – Clinical evidence for IVD medical devices: scientific validity determination and performance evaluation.* 2012. Available: <https://www.imdrf.org/sites/default/files/docs/ghtf/final/sg5/technical-docs/ghtf-sg5-n7-2012-scientific-validity-determination-evaluation-121102.docx> [\[imdrf.org\]](https://www.imdrf.org)

Global Harmonization Task Force. *GHTF/SG5/N8:2012 – Clinical evidence for IVD medical devices: clinical performance studies for in vitro diagnostic medical devices.* 2012. Available: <https://www.imdrf.org/sites/default/files/docs/ghtf/final/sg5/technical-docs/ghtf-sg5-n8-2012-clinical-performance-studies-ivd-medical-devices-121102.pdf> [\[imdrf.org\]](https://www.imdrf.org)

International Organization for Standardization. *International vocabulary of basic and general terms in metrology (VIM).* 2nd ed. Geneva: ISO; 1993. Available: https://www.oiml.org/en/files/pdf_v/v002-200-e07.pdf (later edition but authoritative source) [\[oiml.org\]](https://www.oiml.org)

International Organization for Standardization. *ISO/IEC 17011:2004 – Conformity assessment: General requirements for accreditation bodies accrediting conformity*

assessment bodies. Geneva: ISO; 2004.

Available: <https://www.iso.org/standard/29332.html> [[iso.org](https://www.iso.org/)]

Joint Technical Committee CH-026. *Australian and New Zealand Standard (AS/NZS 2243) – Safety in Laboratories*. Sydney: Standards Australia; 2005.

(Closest accessible source is the updated AS 2243.1:2021 as historical 2005 edition is paywalled.)

Available: <https://www.normsplash.com/Samples/AS/186627787/AS-2243.1-2021-en.pdf> [[normsplash.com](https://www.normsplash.com/)]

Merlin T, Weston A, Tooher R. Extending an evidence hierarchy to include topics other than treatment: revising the Australian 'levels of evidence'. *BMC Med Res Methodol*. 2009;9:34.

Available: <https://link.springer.com/article/10.1186/1471-2288-9-34> [link.springer.com]



Australian
Commission on
Safety and Quality
in Health Care

T. +61 2 9126 3600
Level 5, 255 Elizabeth St
Sydney NSW 2000 Australia

[safetyandquality.gov.au](https://www.safetyandquality.gov.au)

© Australian Commission on Safety and Quality in Health Care 2025